Wed, Jul 30, 2014, 11:58 AM EDT - U.S. Markets close in 4 hrs 2 mins

Recent

% | $
Click the to save as a favorite.

Dendreon Corp. Message Board

  • dinepat203 dinepat203 Jun 18, 2013 1:10 PM Flag

    BREAKING ...JNJ BUYING ARAGON...BECAUSE ZYTIGA IS FAILED TREATMENT....

    JNJ realized very late that Zytiga can not work better than Provenge.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Zytiga can not work better than Provenge"
      JNJ is kind of late to realize that ! It's a known fact...1st, who want to use steroid ? 2nd, who wants to castrate oneself chemically ?

      • 1 Reply to havenger2001
      • Major drug makers such as J&J have been aiming to improve their drug pipelines and expand uses of older drugs to improve their overall profitability.

        The deal includes Aragon's androgen receptor antagonist program, which includes the company's lead product candidate--known as ARN-509--for prostate cancer. The treatment is in Phase 2 development. Aragon's other assets will be spun off into a new company in which J&J won't have an ownership stake.

        "ARN-509 complements Zytiga and provides the potential for exciting, novel approaches to treat prostate cancer patients," said Peter F. Lebowitz, global therapeutic area head, oncology for J&J's Janssen research and development unit. "Prostate cancer is one of our main areas of focus."

 
DNDN
2.13+0.03(+1.43%)11:58 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.